Somasundar P, Krouse R, Hostetter R, Vaughan R, Covey T
Department of Surgery, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
J Surg Oncol. 2000 Aug;74(4):286-90. doi: 10.1002/1096-9098(200008)74:4<286::aid-jso9>3.0.co;2-c.
This study is a review of 14 patients with paragangliomas between 1986 and 1996. The purpose was to determine the sites of origin, clinical manifestations and analyze the benefits of different treatment modalities.
There were 20 tumors in 14 patients. Three (21.0%) of the patients had familial history. There were 7 (50%) females and 7 (50%) males. Anatomically 14 (70%) tumors were in head and neck, 5 (25%) were in the retroperitoneum, one (5%) was in the heart. Of the head and neck tumors 9 (64.25%) were in the carotid body, 3 (21.42%) were found in the vagus, and 2(14.33%) were found in the middle ear. The tumor found in the heart was in the atrial septum. The clinical behavior of paragangliomas is determined by cellular characteristics, secreting capabilities and tumor location. The symptoms and signs depend on the site of origin and the stage at which it presents. The clinically functioning tumors were 3 (17%) in our experience and they typically present with uncontrolled hypertension. The carotid body and mediastinal tumors usually manifested as asymptomatic masses. The intravagal tumors presented with paresis of the nerve. Malignancy rarely occurs and is defined by the existence of metastasis rather than by histology. In our series 2 (10%) of the patients presented with metastasis to lymph nodes, and the vertebrae. The diagnoses in our patients were established by CT and MRI scanning. Angiography was performed in 5 patients with carotid body tumor, two of whom underwent therapeutic embolization to reduce the tumor size. The mainstay of treatment was surgical removal, though radiation has been advocated for patients who cannot undergo surgery.
All patients underwent successful surgical resection of the tumor after appropriate preoperative preparation. Late mortality occurred in two (12.5%) patients at 3 and 5 years from unrelated etiology. Four (25%) patients were lost to follow-up. Three (18.7%) patients developed new primaries, two of them at two years and one after 8 years. One (6%) patient developed recurrent paraganglioma after remaining disease free for 20 years.
In conclusion, paragangliomas are rare with multicentricity being more common in patients with familial history. The malignant potential of the tumor is determined by metastasis as there are no characteristic cellular change. Aggressive surgery is mandatory to obtain disease free survival with low morbidity and mortality. Recurrences can also be successfully operated with low morbidity.
本研究回顾了1986年至1996年间的14例副神经节瘤患者。目的是确定肿瘤的起源部位、临床表现,并分析不同治疗方式的疗效。
14例患者共发现20个肿瘤。3例(21.0%)患者有家族史。女性7例(50%),男性7例(50%)。从解剖学角度看,14个(70%)肿瘤位于头颈部,5个(25%)位于腹膜后,1个(5%)位于心脏。在头颈部肿瘤中,9个(64.25%)位于颈动脉体,3个(21.42%)位于迷走神经,2个(14.33%)位于中耳。心脏中的肿瘤位于房间隔。副神经节瘤的临床行为由细胞特征、分泌能力和肿瘤位置决定。症状和体征取决于起源部位和出现时的阶段。根据我们的经验,临床上有功能的肿瘤为3例(17%),通常表现为难以控制的高血压。颈动脉体和纵隔肿瘤通常表现为无症状肿块。迷走神经内的肿瘤表现为神经麻痹。恶性情况很少发生,其定义是存在转移而非组织学表现。在我们的病例系列中,2例(10%)患者出现淋巴结和椎骨转移。我们患者的诊断通过CT和MRI扫描确定。5例颈动脉体瘤患者进行了血管造影,其中2例接受了治疗性栓塞以缩小肿瘤大小。治疗的主要方法是手术切除,不过对于无法进行手术的患者也有人主张采用放疗。
所有患者在进行适当的术前准备后均成功进行了肿瘤手术切除。2例(12.5%)患者在术后3年和5年因无关病因发生晚期死亡。4例(25%)患者失访。3例(18.7%)患者出现新的原发性肿瘤,其中2例在2年后出现,1例在8年后出现。1例(6%)患者在无病生存20年后出现副神经节瘤复发。
总之,副神经节瘤罕见,家族史患者多中心性更为常见。肿瘤的恶性潜能由转移决定,因为没有特征性的细胞变化。积极的手术对于获得低发病率和死亡率的无病生存至关重要。复发肿瘤也可通过低发病率的手术成功治疗。